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The FAM3 superfamily member ILEI加Ieliorates Al血eimer's disease-like
pathology by destabilizing the penultimate amyloid一帥recursor
(FAM3スーパーフナミリーメンバーILEIはアミロイドβの直前の前駆体を
不安定化することによりアルツハイマー病棟病理を軽減させる)
Aim of the study:
Alzheimer's dis鮎e (AD) is血e most common cause of dementia in the elder抄. Deposition of
aggregated amyloid-p (Aβ) h血e brain, c凱ised by persistent imもalance between production and clearance, is
cen加1 to the pathog甲esis of AD, and reduction of brain AJ3 is the goal缶r disease-modifying therapies.
Carboxyl-terminal舟喝ments (CTFs) of amyloid precursor protein (APP) are cleaved by the †-secretase
complex to release Aβ. Therefore, the y-secretase complex, which primarily contains pres印ilin, nic醐血,
APH-1 and PEN・2, is a major target for therapeutic intervention. Besides APPくTFs, y-secretase cleaves
many other transmembrane protei鮎including No紅h, which is ess血1 to pivotal physiological hnotions.
Applicationもf no飛-selective Y・馳cretase inhibitors has caused serious adverse e飴cts due to blockade of
Notch signaling訂id accumulation of ueurotoxic APP-CTFs. To overcome these limitations, novel
也erapeutic str細gies are needed. In this study, we aim to search for novel proteins which are able to reduce
AP gen併ation thro喝h interaction with the †・S郎rぬse compl既without inhibiti喝岬retase activity.
Methods:
l. Ide鵬i石cation of a novel v-se∝etase binding卸otein ILEl: We e汀岬Ioyed tandem affinity-t喝purification
(TAP) followed by liquid chrom誠ography-tandem mass呼細metric an叫sis. Co-immunoprecipitation
(co-IP) and chemical cross-linking were usd to con触m protein-protein interactions. 2-dimensional (2D)
Blue Native (BN) SDS-PAGE was used to andy功protein complex.
2. Analysis ofILEI effects on Aβ metabolism in v加: ILEI expression level was manipulated by transfection
with CDNA or siRNA. Recombinant ILEl was purr鮎d舟om conditioned medium of cultured cells.臥ISA
and We細n biotti喝were used to evaluate ILEI触ictions in cultu帽d ce一ls.
3. Examin誠on of [LEI expressionJ?i vrvo: ILEI expression in brains of wild-type C57/B6J mice was
assessed by l皿munohist餌hemistry ¢HC). Western blotting and ELISA were used to anabze extracts舟om
organotypic brain slice cultures. Western bio廿ing was u沖d to analyze human autopsy brains.
4. Aれalvsis of ILEI軸notions in vivo: Neuron一坤ecific ILEI-overel甲ressing廿ansgenic (ILEI-T由mice were
gener由d. Double transgenic (DT) mice were obtained by crossbreeding ILEI-Tg and APP-Tg mice, which
hd been wide抄used as AD model叫ce. Mice of each genotype were character!加d by W細blotti鴫,









1. ILEI binds to the v-secretase compl既. One of血e identi鮎d peptides derived hm the isolated ㌣secretase
complex matched r郎Idues 164-179 0f human ILEI. Co-IP and 2D-BN SDS-PAGE indicated interaction
betwe飢TL別and the y-secretase complex. In s触chemical crosslinkmg followd by co-IP demon跡地d that
ILEl directly binds wi姐pres餓ilin lく汀F・
2. ILEI搾duces AS generation bv destabilizing APnCTFs. Knockdown of endogenous nEl increased Ap
secretion, while over叩ression of lLEI decreased A|3 secretion in cultured cells. However, ILEI knockdown
did not a戯由t Notch cl飽Ⅴ喝es or y-secretase activity. Then, we observed that ILEI knockdown r蜘Ited in
舶cumulation of APP-CTFs through extending their half-lives. CTFs °fLRP and N-cadhenn, other substrates
of γ-secretase, we帽un曲cted by ILBI kmkdown, s喝gesting that ILEI specifical抄destabilizes
APP-CTFs.
3. 】LEI extracellularly w°rics through interfenn耳substrate-ぬbilizing capability of oresenilin 1. In cultured
cells, treatments with recombinant ILEI reduced both intracellular APP-CTFs and secreted Ap in a
dose-dependent m鋤乃er, which indicated that ILEI might如Iction細ceJIularly. Recombinant ILEI was
endo叫osed into cultured cells and associated with intracellular y-secretase complexes. ILEPs免motions
depended neither on y-secretase activity nor competition w抽y-secretase即bstrates, but on its bindi喝with
pres印ilin. mEl and APP-CTFs did not share a similar binding domain ofpresenilin.
4. nEl exhibits neuron-specific expression in mouse and human brains. ILEI was widely expr餌sed in
neurons of the central nervotJS野stem. TGF-P treatments decreased Aβ generation through up-regulating
protein levels of lLEl in cuitured rat brain slices. Levels of secreted ILEI decreased dramatically in brains of
AD patients compared to喝e-match control or non-AD neurological diseases patients.
5. ILEI ameliorates the phcnotypes ofAD model mice, Compared to wild-type mice, ILEI-Tg mice showed
decrease in APP-CTFs and Aβ and unaltered Notch cleavages in brains. In DT mice, deficit of the sp誠al
working memory m the Y maze test was闘糟Cud to a wild一秒pe control level. Compared to APP-Tg mice, Ap
toad in brains ofDT mice decreased dramatically as accessed by IHC and ELISA.
D血cussion:
In this study, we ident坤a novel secretory protein ILEI, which regulates the me血otism of
A即しCTFs by perturbi喝substrate-stabilizing cap曲ility of presenilin without altering y-secretase虹tivity.
This unique mechanism allows ILEI to reduce AjJ and neurotoxic APP-CTFs at the same time without
interrupt!喝Odl餅crucial physiological events mediated by γ-secretase activity. Also, the amount of ILEI in
human au叫野brains was negatively correlated with the amount of AP or phosphorylated tau, indicating a
strong correl叫on between ELEI and AD pathology. Most importantly, expression of ILEI in AD model mice
rescued both memory deficits and amyloid d甲osition, suggesting considerable po輸ntial for clinical use in
血ture.
Conclusion:






(学位論文審査の結果の要旨) (明朝体1 1ポイント、 600字以内で作成のこと。 )
アルツハイマー病患者脳に見られる病理所見として、 Aβタンパク質の蓄積が挙げられ、 A
β産生を抑制する物質は新たな治療薬の候補となりうるO　アミロイド前駆体タンパク質(App)
からAP産生の鍵を握るγセクレターゼと相互作用するタンパク質として、 ILEIを同定し、そ
の性質について詳細な解析を加えた。
その結果、以下の点を明らかにした。
1. ILEIが、 Yセクレターゼ複合体の1つであるプレセニリンのC端と結合し、シャペロン機
能を修飾する。
2. ILEIが、 APPからβセクレタ-ゼ切断を受けたC・端断片を不安定化させることで、その後
Yセクレターゼによって産生されるAβ量を低下させる。
3. APP向様にでセクレターゼの基質であるNotchの切断に対しては、効果を青さない。
4.神経細胞特異的にILEIを発現するトランスジェニックマウスを作製し、アルツハイマー
病モデルマウスと交配して解析することにより、 ILEIの過剰発現が老齢アルツハイマー
病モデルマウスにおけるAβ蓄積を低下させ、その結果として記憶の障害を軽減させる
ことを見出した。
本論文は、 A β産生量を調節する新規タンパク質ILEIについて新しい知見を与えたものであ
り、最終試験として論文内容に関連した試問を受け合格したので、博士(医学)の学位論文に
値するものと認められた。
(総字数5 5 8字)
(平成26年9月1日)
